We examined the prevalence of use and cost impact of DPP-4 inhibitors and GLP-1 receptor agonists in people with diabetes.
Brandeis Seymore, RPh
Advertisement
Articles by Brandeis Seymore, RPh
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves XFG-Adapted COVID-19 Vaccine, mRNA for the 2026-2027 Season
2
What Heidi Overton's FDA Nomination Could Mean for Pharmacy
3
FDA Approves First Oral Drug for Dermatomyositis
4
FDA Approves Bixlenvo Once-Daily Single-Tablet Regimen for Virologically Suppressed Adults With HIV
5